NCT01483911View on ClinicalTrials.gov

ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
RSV Infection
Interventions
BIOLOGICAL

ALX-0171

Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.

BIOLOGICAL

Placebo

Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.

Trial Locations (1)

Unknown

Groningen

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT01483911 - ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter